Drug Profile
Research programme: lipoic acid derivatives - Cornerstone Pharmaceuticals Inc
Latest Information Update: 19 May 2022
Price :
$50
*
At a glance
- Originator Cornerstone Pharmaceuticals
- Developer Cornerstone Pharmaceuticals Inc
- Class
- Mechanism of Action Pyruvate dehydrogenase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer